Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4(+) T cells of aviremic HIV(+) individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of lat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Archin, Nancie M., Kirchherr, Jennifer L., Sung, Julia A.M., Clutton, Genevieve, Sholtis, Katherine, Xu, Yinyan, Allard, Brigitte, Stuelke, Erin, Kashuba, Angela D., Kuruc, Joann D., Eron, Joseph, Gay, Cynthia L., Goonetilleke, Nilu, Margolis, David M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2017
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531421/
https://ncbi.nlm.nih.gov/pubmed/28714868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI92684
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares